CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Overview of attention for article published in Multiple Sclerosis and Related Disorders, January 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 24 X posts from 20 X users, with an upper bound of 60,486 followers.

@GrumpyoldGould @iamsuzannehicks 8 months is really fast - you should plan for longer and hope to be pleasantly surprised. Only ~50% of people repopulate within 9 months. https://t.co/So7sUkVdc1

RT @KlausSchmierer: Indeed, and in my opinion, pwMS should also be made aware of the data suggesting similar efficacy, yet better safety, w…

Indeed, and in my opinion, pwMS should also be made aware of the data suggesting similar efficacy, yet better safety, with extended interval dosing on IV #Bcell depleting therapies https://t.co/IO4lE5ZPAh https://t.co/qUXVfe8EjQ https://t.co/bXeIZE8lE1 @pr

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 20 additional X posts.